[Persistent granulocytosis and hyperuricemia after a single G-CSF injection (Filgrastim) in treatment of chemotherapy-induced myelosuppression in metastatic breast carcinoma].
We report about a patient with metastatic breast cancer treated with chemotherapy regime (CMF), who developed a febril leukopenia as well as a hyperuricemia. A single subcutaneous application of 300 micrograms Filgrastim led to a severe overstimulation with leukocytosis of max. 50,000 for about 8 days and hyperuricemia.
Hofmann
M
M
Universitätsfrauenklinik Mainz.
Mahlke
M
M
Casper
F
F
Brockerhoff
P
P
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects*; D001943:Breast Neoplasms / Q000097:blood / Q000628:therapy*; D002278:Carcinoma in Situ / Q000097:blood / Q000628:therapy*; D018270:Carcinoma, Ductal, Breast / Q000097:blood / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D000069585:Filgrastim; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects*; D006098:Granulocytes / Q000187:drug effects*; D006801:Humans; D007279:Injections, Subcutaneous; D007958:Leukocyte Count / Q000187:drug effects; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D018714:Radiotherapy, Adjuvant; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D014527:Uric Acid / Q000097:blood*
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D014527:Uric Acid; D003520:Cyclophosphamide; D000069585:Filgrastim; D005472:Fluorouracil; D008727:Methotrexate